Chapter 11: Antianginal Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine for a second you have an engine,

a really high -performance engine, top of the line.

Okay.

It's designed to run 24 -7, never stopping, for decades on end.

It's got incredible torque, amazing efficiency, but there's a catch.

This engine consumes a massive amount of fuel.

Right.

And the fuel lines, they are getting a little, let's call it crusty, maybe a little clogged with gunk.

You are describing the human heart in the throes of coronary heart disease.

Exactly.

The engine is still revving, the driver is stepping on the gas, but the fuel line, the coronary artery,

just can't deliver the goods.

The supply can't meet the demand.

That mismatch, that is the essence of angina.

And today we aren't just skimming the surface of chest pain.

We are opening up the hood to see exactly how the mechanics try to fix that engine while it's still running.

We certainly are.

We are looking at chapter 11, anti -anginal drugs from Brenner and Stevens Pharmacology, sixth edition.

And I'm glad you used the engine metaphor because this chapter is essentially a manual for biochemical mechanics.

And just to set the expectations here, this is our mission for this deep dive.

We want to create the ultimate audio companion for the pharmacology student or really anyone who wants a med school level breakdown of how we treat a starving heart.

We are going to walk through this chapter linearly, decoding the mechanisms, the drug classes, and the clinical strategies without getting bogged down in the dense jargon that usually puts people to sleep.

That's the goal.

We want to connect the dots between the physiology, what the heart is doing, and the pharmacotherapy, how the drugs fix the problem.

Because it's not enough to just memorize a drug name.

You have to understand the mechanics.

If you understand the why, the what is easy to remember.

So here's our roadmap.

We're going to start with the landscape of coronary heart disease, what is actually going wrong.

Then we move to the physics of the heart,

specifically the supply versus demand equation.

A crucial concept.

Then we break down the big players, nitrates, calcium channel blockers, beta blockers.

We've got some fascinating newer agents to talk about, and we'll wrap up with how doctors actually manage this in the real world.

It's a comprehensive journey.

It covers everything from old school explosives to cutting edge metabolic hackers.

It's really a fascinating field.

Okay, let's dive in.

Let's start with the landscape.

The text mentions coronary heart disease or CHD, but it breaks it down into a spectrum.

We aren't just talking about one thing here.

It feels like people use heart disease as a catchall, but clinically there are distinct categories.

Right.

And that's the first thing you have to get straight.

CHD is the umbrella term.

It basically means the plumbing to the heart muscle is compromised.

The fuel lines are clogged.

Exactly.

But under that umbrella, you have two main categories based on how the symptoms present and really the immediate danger level.

You have chronic angina pictoris, which is most often called and then you have the acute coronary syndromes.

Which sounds a lot scarier.

Acute coronary syndrome sounds like something you hear right before the flatline noise in a medical drama.

It is significantly more dangerous.

That's the emergency.

Acute coronary syndromes, or ACS, include unstable angina and myocardial infraction, or MI,

a heart attack.

So help us distinguish these in plain English.

What is the difference between stable and unstable angina?

Is it just that one hurts more?

Not necessarily.

Pain is subjective.

The real distinction is about predictability and the underlying mechanism.

Stable angina is by its very definition predictable.

It respects the rules of physics.

It typically happens with exertion.

You're running for a bus or you're shoveling heavy snow or you're lifting a heavier box.

That physical effort increases the heart's demand for oxygen.

The engine raise higher.

Right.

But because there's an atherosclerotic plaque, a fixed hardened narrowing in the artery, the supply can't keep up.

The fuel line is physically too narrow to deliver more fuel on demand.

It's the supply and demand mismatch we talked about.

The engine revs up.

The fuel line is pinched.

The engine sputters.

Exactly.

The patient feels a heavy weight or pressure on the chest.

The classic description is an elephant sitting on your chest.

But, and this is the key to it being stable.

If they stop running or if they put the shovel down and rest, the pain goes away because the demand drops back down to meet the limited supply.

The engine idles down and the narrowed fuel line is sufficient again.

It's a plumbing issue, but it's a stable, predictable plumbing issue.

Okay.

So that's stable.

It plays by the rules.

What makes unstable angina so unstable?

Unstable angina is the wolf at the door.

It breaks that contract of predictability.

How so?

It's unpredictable.

The frequency and the severity of the attacks start increasing over time.

It might happen with less and less exertion or, and this is the really scary part, it might happen when you're just sitting on the pouch watching TV doing absolutely nothing at rest.

That sounds terrifying.

At least with stable angina, you know if you stop running, you'll probably be okay.

Unstable just comes for you.

It does.

And the underlying cause is different and much more active.

In unstable angina, we're usually looking at a coronary vessel that isn't just narrowed, it's being actively occluded.

Actively, like right now?

Yes.

Often, an athermomatous plaque has ruptured.

It's cracked open.

The body sees this as an injury and tries to heal it by forming a clot.

So small platelet thrombi little clots are forming on it, breaking off and clogging the vessel in a real time.

Wow.

Unstable angina is often the forerunner, the massive red flashing warning sign of a full blown heart attack, a myocardial infarction.

It's an emergency.

So stable is a pipe that is too small.

Unstable is a pipe that is actively clogging up right now with debris.

A perfect summary.

But the text mentions a third type, which seems to be the outlier,

variant angina.

Yes, also known as Prince metal angina.

This one is a weird one.

It breaks all the rules we just discussed because it has nothing to do with plaque or exertion in the traditional sense.

So what causes it?

It's caused by acute coronary vasospasm.

Vasospasm.

So the muscle of the artery wall itself is freaking out, clamping down.

Essentially, yes.

For reasons that aren't perfectly understood, the artery itself suddenly constricts.

It just clamps down, shutting off or severely restricting blood flow.

And weirdly, this often happens at rest or even during sleep.

Patients will wake up in the middle of the night with crushing chest pain.

That's terrifying.

You wake up with chest pain and you haven't even been exercising.

Your heart should be at its lowest demand.

It is.

And because the mechanism is completely different, a spasm versus a physical blockage, the treatment is drastically different.

This is a critical point.

The text actually has a great chart, table 11 .1, that compares drug efficacy across these types.

It's sort of a cheat sheet for what works and what doesn't.

It is a crucial table for anyone studying this.

You absolutely have to understand it.

It really highlights why the diagnosis matters so much.

So let's walk through it.

What's the biggest takeaway?

Look at the first row.

Organic nitrates.

They get a plus plus, which means highly effective, across the board.

Stable, unstable, variant.

They work for everything.

They are the universal wrench in this cool kit.

They are.

They are potent vasodilators so they can open up a narrowed vessel and relax a spasming vessel.

They cover all the bases.

Okay.

What are the next one?

Beta blockers.

Now it gets interesting.

For typical, stable angina.

Highly effective.

Another plus plus.

Makes sense.

They slow the heart down, reduce demand.

But then look at variant angina.

Right.

The table gives them a zero.

Or frankly, it should probably give them a negative score.

Zero efficacy.

So they just don't do anything.

They do nothing to relieve the spasm.

In fact, as we'll discuss later, they can actually make variant angina worse.

How is that possible?

By locking the good receptors that cause dilation, leaving the bad receptors that cause constriction unopposed.

It's a classic pharmacology trap.

Wow.

Okay.

So diagnosis is everything.

And then you have the antithrombotics and cholesterol meds, aspirin statins.

Right.

Those are rated highly for preventing MI and death, which is the long -term goal.

They stop clots and stabilize plaques.

But for immediate symptom relief in say, variant angina.

Useless.

An aspirin won't stop a vasospasm.

So we've got the landscape.

We know we're fighting.

Now let's get into the physics.

Section two is all about supply versus demand.

Figure 11 .2 in the text shows this as a balance scale.

This is the fundamental concept of all anti -anginal therapy.

If you take nothing else away from this deep dive, take this.

The goal of every single drug we discussed today is to restore that balance.

You either have to increase the oxygen supply or you have to decrease the oxygen demand.

That's it.

Okay.

Let's start with supply.

This seems straightforward.

It's just blood flow, right?

Open the pipe, get more blood.

On the surface, yes.

But the distribution of that flow is what really matters.

The text highlights a vulnerable zone, the subendocardial tissue.

The subendocardial tissue.

Break that down for us.

Sub means below.

Endocardium is the thin inner lining of the heart chambers.

So this is the layer of heart muscle right underneath that lining, the innermost layer of muscle.

Why is that layer more vulnerable?

Why doesn't it get the same blood as the rest of the heart?

Think about how the plumbing is laid out.

The large coronary arteries sit on the surface of the heart.

That's the epicardium.

They send smaller branches diving deep into the to feed the inner layers.

The subendocardium is at the absolute end of the line.

Like the last house on a dead end street during a water main break.

Exactly.

It gets the lowest pressure and the last drop of blood.

And to make matters worse, that inner layer is under the most physical pressure.

When the ventricle squeezes down to pump blood, that's called systole, it crushes those deep vessels.

So it's squeezing its own blood supply shut.

For a moment, yes.

During systole, the squeezed blood flow to the subendocardium basically stops.

It only gets properly fed during diastole, the period when the heart relaxes and refills.

So if you have a blockage upstream, or if your heart is beating too fast and not spending enough time in that relaxed diastolic phase, that tissue starves first.

It's the canary in the coal mine for ischemia.

So drugs that increase supply like nitrates and calcium channel blockers need to get blood to this specific, very hungry area.

Right.

They dilate the large epicardial vessels to increase total flow, but they also help reduce that compressive resistance so that precious blood can perfuse that hungry subendocardial tissue at the end of the line.

Okay.

That's the supply side of the scale.

Now the demand side, this is where the heart is doing the work.

The text says demand is determined by three main things, heart rate, contractility, and wall tension.

Heart rate and contractility are pretty intuitive.

If the heart beats faster, it squeezes harder, it burns more oxygen.

Like driving your car at a hundred miles per hour burns more gas than driving at 50.

Exactly.

More work, more fuel.

But the third one, wall tension is a little less obvious, but hugely important.

Yeah.

Wall tension sounds like a physics term.

I feel like my eyes gloss over when I see physics in a biology text.

What is wall tension actually?

It is physics, but it's crucial.

Think of wall tension as the stress on the individual muscle fibers.

How hard do they have to pull to hold the heart together against the pressure inside and squeeze the blood out?

The text gives us the formula, which is derived from the law of Laplace.

It says wall tension is roughly proportional to ventricular volume multiplied by pressure and then divided by the wall thickness.

Okay.

Let's unpack that.

Volume times pressure.

Why does volume matter?

A bigger heart has more tension.

Think of the heart like a balloon.

If you blow up a balloon just a little bit, the rubber is loose.

It's relaxed.

But if you blow it up until it's huge and about to pop, the skin of the balloon is incredibly tight.

That tightness is tension.

So a dilated heart, a heart that's overfilled with blood has very high wall tension.

And pressure.

That's how hard the heart has to push to open the door, the aortic valve and eject blood into the body.

If you are trying to blow up a balloon that has really stiff walls, you have to blow a lot harder.

That internal pressure you generate creates tension in the wall.

So to lower oxygen demand, we want to reduce that tension.

We want a smaller balloon and less pressure to push against.

Precisely.

And this leads us to two terms that students always, always mix up.

Preload and afterload.

These are the pillars of hemodynamics.

If you can master these two, you're halfway there.

So let's do it.

What's preload?

P -load is essentially the volume issue.

It's the amount of blood returning to the heart from the veins, filling up the ventricle right before it squeezes.

It's the stretch on the muscle at the end of diastole.

So high preload means a big stretched out balloon.

So if we have less blood coming back to the heart, we have less stretch, less volume, less tension.

Exactly.

That's reducing preload.

Okay.

Then what's afterload?

Afterload on the other hand is the pressure issue.

It's the resistance the heart has to push against to eject blood into the arteries.

It's the squeeze required to open the aorta and push blood out.

So if the arteries are clamped down like in high blood pressure, the afterload is high.

Very high.

And the heart has to generate massive wall tension to overcome it.

It has to burn a ton of oxygen just to get the door open before it's even moved any blood.

So bringing it back to the drugs,

if we lower preload or afterload, we lower wall tension and the engine doesn't have to work his heart.

Precisely.

And here is the general rule of thumb from the text.

A really high yield point.

Nitrates primarily hit the veins.

They are venodilators.

By dilating veins, they cause blood to pool in the periphery so less comes back to the heart.

So nitrates lower preload.

You got it.

And calcium channel blockers.

They primarily hit the arteries.

They are arterial vasodilators.

They dilate the pipes leaving the heart.

This lowers resistance, lowers blood pressure.

So CCBs lower afterload.

Boom.

That is the light bulb moment.

Nitrates equal veins equal preload reduction.

CCBs equal arteries equal afterload reduction.

Both of them ultimately lower the oxygen demand on the heart.

Got it.

You've got the physics down.

Okay.

Let's get into the specifics then.

All right.

Let's go deep on the first class of drugs,

the vasodilators.

Section three in the book is all about the organic nitrites and nitrates.

These seem to be the oldest drugs in the book for this.

They are the old guard.

We're talking about of nitrous and nitric acid.

Their history is actually tied to the invention of dynamite.

Alfred Nobel, the inventor of dynamite, used nitroglycerin.

He actually suffered from angina later in life and his doctors prescribed him nitroglycerin.

Kidding.

No, he refused to take it, ironically.

But factory workers who handled it noticed it relieved their chest pain.

That's how we discovered its medical use.

That's incredible.

So the text lists a few different forms here.

We've got amyl nitride, nitroglycerin, and the isophorbides.

And the kinetics, how they move through the body, seem to be the big differentiator.

They are.

The route of administration and the speed of action are what separates them.

Let's look at amyl nitrite first.

It's unique because it's a volatile liquid.

It comes in a little glass ampule wrapped in cloth.

You crush it and inhale the vapors.

And it works fast.

Extremely fast.

On set within 30 seconds.

But it's also gone just as A total flash in the pan.

It's rarely used for angina anymore because it's so fleeting and smells terrible.

But it has other more specific uses we can touch on.

Okay, so then you have the big one, nitroglycerin.

The text calls it a shapeshifter because it comes in so many forms.

It really does.

It's the most versatile.

The classic form is the sublingual tablet.

You place it under the tongue for an acute attack.

Why under the tongue?

The mucosa under your tongue is very thin and incredibly rich in blood vessels.

The drug gets absorbed directly into the systemic circulation by passing the liver and getting right to the heart.

It works in minutes.

But the text says if you swallow that same tiny tablet, it's pretty much useless.

Why?

Because of something called the first pass effect.

The liver is our body's main detoxification center.

When you swallow a drug, it gets absorbed from the gut and goes straight to the liver via the portal vein.

And the liver has a specific enzyme organic nitrate reductase that just hunts the stuff down and chews it up.

So it gets destroyed before it can do its job.

Exactly.

The liver destroys about 90 % of an oral dose of nitroglycerin before it ever reaches the heart.

So oral doses have to be massive compared to sublingual ones just to get a little bit through.

That's why we have patches and ointments to get around the liver.

Precisely.

Transdermal patches release the drug slowly and consistently through the skin, bypassing the liver initially and providing 24 -hour coverage.

Well, almost 24 -hour coverage, but we'll get to the problem of tolerance in a moment.

And finally, the isorbides, dinitrate and mononitrate.

These sound like chemical tongue twisters.

These are the long distance runnels in the group.

They have a slower onset of action, but a much longer duration.

They're used for prevention, not for acute attacks.

What's the difference between dinitrate and mononitrate?

It's a neat little pharmacokinetic trick.

Isorbide dinitrate is actually a pro -drug.

It gets converted in the liver into isorbide mononitrate, which is the active compound.

So the mononitrate is what's actually doing the work.

Right.

So when you prescribe the mononitrate form directly, you're just cutting out the middleman and getting straight to the active drug.

It gives you more predictable blood levels.

Now let's get to the mechanism.

This is the core of it.

How did these drugs actually cause the vessel to relax?

Figure 11 .3 in the text is the key here.

Walk us through the cellular animation.

It is a beautiful cascade.

So imagine we're inside a smooth muscle cell that's wrapping around a blood vessel.

The organic nitrate enters the cell.

It's a pro -drug, remember?

So it's inactive until it gets processed.

Inside the cell, enzymes break it down to release free nitric oxide, or NO.

The magic gas.

NO is a gas that acts as a powerful signaling molecule.

It diffuses out and activates an enzyme in the cell called soluble guanilil cyclase.

Think of this enzyme as a factory machine.

Once you flip the NO switch, it turns on.

And what does this machine produce?

It starts cranking out a second messenger molecule called CGMP.

That stands for cyclic guanosine monophosphate.

So NO turns on the machine.

The machine makes CGMP.

What does CGMP do?

Right.

And CGMP is the star of the show here.

It activates a whole series of other proteins called kinases.

And here is the punchline, the final step.

These kinases target the contractile machinery of the cell.

Specifically, they cause the dephosphorylation of myosin light chains.

Okay, that's a mouthful.

Let's visualize this.

Muscle contraction happens when myosin heads grab onto actin filaments and pull, right?

Like a ratchet.

Exactly.

But for myosin to be able to grab actin, it needs to be primed with energy.

It needs a phosphate group attached to its light chain.

That phosphorylation is what activates the grip.

So the nitrates.

The nitrates via CGMP trigger a process that rips that phosphate group off the myosin.

Dephosphorylation.

So it essentially greases the myosin.

It can't get a grip on the actin.

Exactly.

It makes the myosin head let go.

And if it can't grip, it can't contract.

The muscle fiber has to relax.

The vessel dilates.

And as we said, this happens mostly in the veins, not the arteries.

Predominantly in the veins, yes.

They are more sensitive to this effect.

This causes venous pooling.

Blood hangs out in the legs and the periphery instead of rushing back to the heart.

The less return means lower preload, less wall tension, less oxygen demand for the heart.

And that is how nitroglycerin stops an angina attack.

Now, there's a sidebar in the text that we absolutely have to mention.

Amyl nitrite.

It has a non -medical reputation.

Cloppers.

Yeah.

The text mentions they are abused in the club scene.

Why?

What is the appeal of a medication at a rave?

Well, think about the mechanism we just described.

It causes massive rapid vasodilation, a sudden drop in blood pressure that causes a rush of warm blood to the head, a feeling of euphoria or a rush that lasts a minute or two.

Okay.

So a head rush.

And as the text politely puts it, it relaxes involuntary smooth muscles throughout the body.

Which has implications beyond blood vessels.

Indeed.

It relaxes sphincter muscles, for example, which is why it became popular in some subcultures to reportedly enhance sexual pleasure.

But it's not a free lunch.

The text lists some very serious risks.

It's not just a harmless party drug.

No, absolutely not.

We're talking about significant immune system suppression with chronic use,

red blood cell dysfunction.

It can cause something called methamoglobinemia and of course, overdose.

And the risk if you combine it with other drugs.

If you combine poppers with other vasodilators like alcohol or heaven forbid, a PDE -5 inhibitor like Viagra, you can drop your blood pressure so low, you essentially stroke out or have a heart attack.

It's incredibly dangerous.

But weirdly enough, amyl nitrite has a legitimate life -saving medical use that has nothing to do with the heart.

Cyanide poisoning.

This feels like a spy movie plot point.

This is one of those classic pharmacology facts that every medical student has to learn because it saves lives.

Cyanide is a deadly poison because it shuts down your mitochondria.

It stops your cells from being able to use oxygen.

It causes cellular suffocation.

Okay.

Amyl nitrite works by oxidizing the iron in your hemoglobin, changing it from the ferrous form to the ferric form.

This creates a version of hemoglobin called methamoglobin.

Which usually is bad, right?

We want regular hemoglobin to carry oxygen.

Usually, yes, methamoglobin is bad because it doesn't carry oxygen well.

But it has a huge, huge affinity for cyanide.

It acts like a sponge or a trap.

Ah, so it pulls the cyanide away from your blood.

Or it's doing damage.

Exactly.

It pulls the cyanide out of the mitochondria and binds it safely in the blood, forming something called cyanomethamoglobin.

This protects the mitochondria, buying the emergency services precious time until they can administer the true antidote, sodium thiosulfate, to clear the poison out of your system.

That is wild.

A poison antidote hidden in an abused heart medication.

It's a fascinating and elegant mechanism.

Okay.

Let's talk about the major downside of nitrates for angina.

There's a phenomenon called Monday disease.

The text alludes to this with the concept of tolerance.

This is a real historical thing, right?

It is.

And it's a perfect illustration of drug tolerance.

In the early 20th century,

workers in explosives factories were handling nitroglycerin all day long.

They were absorbing massive amounts of it through their skin.

What happened to them?

Did they just feel dizzy all the time?

Well, on Mondays, they would come to work after the weekend and get these terrible throbbing headaches and feel dizzy and flushed.

That's the vasodilation working too much blood rushing to the brain.

Okay.

But by Tuesday or Wednesday, they felt fine.

Their bodies had adjusted.

They developed tolerance.

The drugs stopped affecting them so strongly.

So their bodies got used to it.

Yes.

But then they would go home for the weekend,

no exposure on Saturday or Sunday.

Over those two days, they would lose their tolerance.

So when they came back Monday morning were exposed again, bam, headache city.

That was Monday disease.

But there was a darker side to this too, wasn't there?

The text mentions some workers experienced angina over the weekend.

Exactly.

This is the really tragic part.

Some of these workers had underlying coronary heart disease they didn't even know about.

During the week, the factory environment was basically treating their angina without them knowing it.

But over the weekend, a withdrawal phenomenon would hit.

Their tolerance would disappear and they'd get rebound vasoconstriction.

So their arteries would clamp down harder than normal.

Right.

And they'd get chest pain or even have heart attacks on Sundays because their coronary arteries were suddenly constricting again, starved of the drug they'd become dependent on.

That is fascinating and tragic.

So how do we apply that lesson to patients using nitrate patches today?

We have to mimic the weekend.

We have to give the body a from the drug.

Literally, we cannot provide continuous 200 and four seven coverage.

What does that look like in practice?

If a patient uses a transdermal patch, they need a patch off time.

The standard recommendation is to have a nitrate free interval of at least 10 to 12 hours a day.

Usually they take the patch off at night while they sleep.

We had to simulate the weekend every single night to prevent the Monday tolerance.

Exactly.

That drug free period allows the body's sensitivity to the drug to reset.

And what causes this tolerance?

Why does the body stop listening to the drug after a while?

It's still being researched, but the leading theory involves free radicals and enzyme depletion.

The text suggests that the enzymes responsible for converting the nitrate to active NO, specifically an enzyme called mitochondrial aldehyde dehydrogenase or ALDH2, get inactivated.

Essentially, the process of releasing nitric oxide from the drug generates damaging free radicals as a byproduct.

These free radicals then attack and gum up the very machinery that's creating them.

You burn out the enzyme.

So you need that drug free interval to allow the cell to repair and regenerate that enzyme.

Precisely.

To clean up the mess and rebuild the factory.

Got it.

Now adverse effects.

If you dilate all the blood vessels, what happens?

What does the patient feel?

You get the symptoms of too much blood flow to the wrong places at the wrong times.

Head rush symptoms are the classic ones.

Headache is very, very common due to the dilation of the meningeal arteries in the covering of the brain.

Okay, so headache.

What else?

Flushing of the face because of dilated skin vessels.

Dizziness, especially when standing up quickly.

That's orthostatic hypotension.

And something called reflex tachycardia.

This seems important.

This is critical to understand.

When you cause widespread vasodilation, the blood pressure drops.

The body has sensors, called baroreceptors, in the neck and aorta that detect this.

And they panic.

They panic.

They send an emergency signal to the brain saying, hey, pressure is dangerously low.

We might be bleeding out.

The brain's response is to flood the system with adrenaline and tell the heart, speed up, pump faster to get the pressure back up.

So the heart rate spikes tachycardia.

Right.

Which is exactly what we don't want in a patient with angina.

A speeding heart needs a huge amount of oxygen.

So the drug's benefit is being canceled out?

It can be.

We gave the drug to save oxygen and the body's reflex is now burning more oxygen.

That's why we often have to pair a nitrate with a beta blocker.

The beta blocker prevents that reflex acceleration of the heart.

One final, absolutely crucial warning on nitrates.

The text has a big red flag about drug interactions.

A very famous and very deadly drug interaction.

The sildenafil interaction.

Viagra, Cialis, Levitra, the whole class of drugs known as PDE5 inhibitors.

Why is this combination so deadly?

Is it just too much of a good thing?

Too much vasodilation?

It's a perfect storm at the molecular level.

It's about that CGMP pathway we discussed earlier.

Remember CGMP, the messenger molecule that causes the muscle to relax?

Yes, the thing that nitrates help produce.

Right.

Well, the body has a natural off switch to clean up that CGMP once its job is done.

The enzyme that breaks down CGMP is called phosphodiesterase type 5 or PDE5.

And sildenafil.

Sildenafil and its cousins work by blocking that enzyme.

They inhibit PDE5.

They prevent the breakdown of CGMP so its levels rise, which is how they work for erectile dysfunction.

And nitrates work by making more CGMP.

Do you see the problem?

You have one drug stepping on the accelerator to make more CGMP and another drug cutting the brake line so you can't get rid of it.

Disaster.

You get a massive uncontrolled synergistic accumulation of CGMP.

The smooth muscle in the blood vessels relaxes completely.

The blood pressure just tanks.

It bottoms out.

It can cause profound irreversible hypotension leading to a heart attack or stroke.

You absolutely never ever mix these.

If a patient takes a PDE5 inhibitor, they cannot touch a nitrate for at least 24 hours.

It's a life or death contraindication.

Okay, that's a clear and serious warning.

Let's move to the second class of vasodilators.

The calcium channel blockers, or CCVs.

A very diverse and important group.

Unlike nitrates, which are all kind of variations on a theme, CCVs are really split into two very different families with different jobs.

The dihydropyridines and the non -dihydropyridines.

I feel like these names were designed to make pharmacology students cry.

They are a mouthful.

But there's a simple trick.

The dihydropyridines are the ones that end in the suffix adipine.

Think amlodipine, nefdepipine, philodipine.

The dipipines, that's manageable.

And the non -dihydropyridines are basically the other two you need to know.

Verapamil and diltiasm.

And the difference isn't just the spelling.

It's where they work, right?

The text stresses their selectivity.

A huge difference.

The dipines are potent vasodilators.

They work almost exclusively on the smooth muscle of the blood vessels, especially the arteries.

They relax the pipes.

Verapamil and diltiasm are less selective.

They work on the vessels and directly on the heart muscle itself.

Let's look at the mechanism first.

Back to figure 11 .3 again.

How do they block calcium?

What are they actually doing?

They block a specific type of calcium channel called the L -type calcium channel.

The L stands for long -lasting.

These are voltage -gated channels found on the membrane of muscle cells.

Voltage -gated, meaning they open when an electrical signal arrives.

Exactly.

When the electrical signal hits the cell, these doors are supposed to open, and calcium rushes into the cell from the outside.

And calcium is the ultimate trigger for contraction.

It's the key in the ignition.

Calcium binds to a protein called calmodulin.

The calcium calmodulin complex then activates another enzyme, myosin light -chain kinase.

That's the enzyme that puts the phosphate on myosin and makes it grip.

So the CCBs.

The CCBs essentially stand in the doorway of the L -type channel.

They lock the gate.

No calcium can get in from the outside.

No calcium influx means no calcium calmodulin complex.

No complex means the kinase stays asleep, the muscle stays relaxed.

Simple enough.

But let's look at table 11 .3 in the book, which interprets the selectivity of these drugs.

This is where the clinical choice happens.

Why would I choose a dipapine over verapamil or vice versa?

Okay, look at the column for the dihydropyridines, like nefetapine or hamlotapine.

See the effect on coronary blood flow.

Huge increase.

Three plus signs.

Exactly.

They are fantastic at dilating arteries and increasing supply.

Great afterload reducers.

But now look at the rows for heart rate and contractility.

It says reflex increase for heart rate and no effect.

Or a slight decrease for contractility.

Right.

Because hamlotapine drops the blood pressure so effectively by opening up the arteries, it can trigger that same reflex tachycardia we saw with nitrates.

The baroreceptors panic again.

They panic again.

The dipamins don't block the heart's electrical system, so the heart is free to race in response to that sudden drop in pressure.

But then look at verapamil and diltiasms columns.

It's a completely different story.

Yes, they cause vasodilation, but look at the heart.

They cause a significant depression of the SA and AV nodes.

And a significant reduction in contractility.

Two or three minus signs.

So they act like a break on the heart itself.

A powerful break.

They directly slow the heart's firing rate and weaken the force of its squeeze.

So verapamil is almost like a beta blocker in disguise in terms of its effect on heart rate.

In terms of its functional effect on heart rate and contractility, yes, it puts the brakes on, which is great for reducing oxygen demand, but can be very dangerous if the patient already has a wheat heart, like in heart failure.

You don't want to put a powerful brake on a car that's already struggling to move uphill.

Okay, let's touch on pharmacokinetics for a second.

Table 11 .2 shows most of these are absorbed but get hammered by the liver -high first -pass metabolism again.

Yes, that's a common theme.

But there is a safety note in this section that is incredibly important, specifically regarding nifedipine.

Short -acting nifedipine.

The text mentions it's associated with an increased risk of MI and mortality.

That sounds bad.

It's very bad.

This is a crucial historical lesson in pharmacology.

In the past, doctors used these little liquid -filled capsules of short -acting nifedipine for hypertensive emergencies.

They'd even have the patient bite the capsule and squirt the liquid under their tongue for faster absorption.

Sounds effective at lowering blood pressure.

Way too effective and way too fast.

It caused such a massive, rapid, jagged drop in blood pressure that it would induce ischemia.

The pressure would drop so fast that blood flow to the brain and heart couldn't keep up.

It was actually causing heart attacks and strokes.

Oh, wow.

So the text is very clear.

Regulatory now recommend against using short -acting nifedipine.

We stick to long -acting or sustained -release formulations that give you a smooth, gentle, controlled reduction in blood pressure.

There's a special use case here mentioned for a drug called nemodpipine.

It's a kicky pine, but it's not for angina, is it?

No, it's not.

It's used specifically for preventing vasospasm after a suberacnoid hemorrhage, a specific and very dangerous type of bleeding stroke in the brain.

Why nematina specifically?

What makes it special?

Because nematina has a high lipophilicity.

It loves fat.

The brain is mostly made of fat and lipids.

So nemodpipine is very good at crossing the blood -brain barrier and concentrating in the brain tissue.

I see.

After one of these bleeds, the brain's arteries are very irritated and prone to spasming, which can cause a secondary stroke.

Nifedipine gets into the brain and dilates those cerebral vessels, preventing that devastating complication.

It saves brain tissue from dying.

But there's a terrifying warning attached to it in the text.

A huge one.

A black box -level warning.

Oral use only.

It's usually a liquid that's drawn up into a syringe, but that syringe must never, ever be connected to an IV line.

What happens if it is?

If you accidentally inject nemodpipine into a vein, it can cause immediate and fatal cardiovascular collapse.

The heart just stops.

It must be given by mouth or squirted down a nasogastric tube.

It's a major safety focus in hospitals.

Yikes.

Okay, side effects for the CCB class in general?

Well, the vasodilation effects, obviously.

Flushing, headache, dizziness, just like the nitrates.

Edema is a big one, specifically peripheral edema.

Swollen ankles.

Yes.

Patients on emilodipine often complain of swollen ankles.

It's not a sign of heart failure.

It's because the drug dilates the arteries so much that it increases pressure in the capillaries and fluid leaks out into the tissue.

And constipation.

That seems random.

Especially with verapamil.

It's not random when you remember that the gut wall is made of smooth muscle.

Verapamil relaxes the smooth muscle of the gut just like it relaxes the arteries.

Peristalsis, the muscular wave that moves food along, slows right down.

And then there's this really weird one.

Gingival hyperplasia.

Gum overgrowth.

It's a strange but classic side effect.

It looks like the gums are swelling up and starting to cover the teeth.

It's not an infection.

It's an actual overgrowth of the gum tissue itself.

If you see a patient with puffy, overgrown gums, you should always check their medication list for a calcium channel blocker, particularly nifedipine.

And one last interaction note.

Digoxin.

Right.

Verapamil and diltiazem, in particular, can increase the levels of digoxin, another heart medication.

They inhibit a transporter in the kidney that's responsible for clearing digoxin from the body.

They compete for the same exit door.

If you mix them, digoxin levels can rise into the toxic range.

All right.

Let's move on to section five.

The beta adrenoceptor antagonists or beta blockers.

We've covered these in depth in other deep dives, but what is their specific role here in angina?

The main players mentioned are Atenolol, Meduprolol, and Propranolol.

Their role in angina is purely on the demand side of the equation.

So they don't increase supply.

No, they don't dilate vessels.

In fact, if anything, they might cause slight vasoconstriction.

Their whole game is to block the sympathetic drive, the effects of adrenaline and noradrenaline on the heart.

So they slow the heart rate and reduce contractility, the force of the squeeze.

Which is a massive saving in terms of oxygen consumption.

And there's a secondary benefit.

By keeping the heart rate low, you increase the amount of time the heart spends in diastole.

The relaxation and filling phase.

Right.

And remember, diastole is when the coronary arteries get their blood flow, especially to that vulnerable subendocardium.

So by slowing the heart, you are actually increasing the feeding time for the heart muscle.

It's a double win.

Less work and more time to eat.

Exactly.

That's why they are a cornerstone for treating typical stable angina and for improving survival after a heart attack.

But, and this is the big but, the text brings up the variant trap again.

This is the classic board exam question and a life or death clinical distinction.

You never, ever give a beta blocker to a patient with variant or Princemetal angina.

Why not?

If they slow the heart and save oxygen, shouldn't that help no matter what's causing the pain?

It's all about the receptors on the blood vessel walls.

The coronary arteries have two main types of adrenergic receptors that respond to adrenaline.

Beta two receptors, which cause dilation and alpha one receptors, which cause constriction.

Okay.

So beta dilates, alpha constricts a balance.

Normally it's a balance system.

Adrenaline hits both and the net effect is managed.

But if you administer a beta blocker, especially a non -selective one like propranolol, you blockade the beta two receptors, you lock the dilate door shut.

So the adrenaline has nowhere to go but to the alpha receptor.

Exactly.

You leave the constrict signal completely unopposed.

If a patient is already prone to vasospasm, this unmasked alpha stimulation can actually trigger or severely worsen the spasm.

It's like throwing gasoline on the fire.

That's a critical piece of information.

So for variant angina, it's CCBs or nitrates only.

Correct.

Avoid beta blockers at all costs in that specific condition.

Now let's get into the future.

Section six of the chapter is called other anti -anginal agents.

These are drugs that don't fit the old molds.

First up, Ivoberdine.

This one sounds like magic.

Ivoberdine is very cool because it's so specific in what it does.

It targets the funny current or Ivoberdine, which is found almost exclusively in the sinoatrial node, the heart's natural pacemaker.

Why is it called the funny current?

Is that an actual scientific term?

It actually is.

Researchers in the 70s called it funny because it behaves oddly compared to other ion channels.

Most channels open when the cell becomes electrically positive or depolarized.

The funny current opens when the cell becomes more negative or hyperpolarized.

It's the current that kicks off the slow depolarization that starts the next heartbeat.

So what does Ivoberdine do to it?

It specifically blocks it.

This slows down the rate of that spontaneous depolarization in the SA node.

The slope of the pacemaker potential flattens out.

The result?

Pure heart rate reduction.

But unlike beta blockers or non -dihydropyridine CCBs, it doesn't weaken the squeeze, it has no effect on contractility, and it doesn't really lower the blood pressure.

It just slows the beat down.

It's a pure negative chronotrope.

That sounds perfect for a patient who can't tolerate the blood pressure drop of other drugs but needs a slower heart rate.

Are there any side effects?

A very specific and weird one.

Visual disturbances.

Specifically phosphenes.

Phosphenes.

What are those?

Flashes of light in the visual field, or seeing halos around lights, or a sort of stroboscopic effect.

Why on earth would a heart drug cause you to see light flashes?

Because biology is efficient and reuses its parts.

The retina in the eye uses very similar ion channels, called HCN channels, to process light signals.

So when you block the funny current in the heart, you inadvertently affect the similar channels in the eye.

It's usually temporary and dose -related, but it can be quite alarming for patients if they're not warned.

Fascinating.

Next up in the new class, ranlozine.

This one seems complicated.

The mechanism involves sodium.

It is a bit more nuanced, but it's a really clever approach.

It blocks the light sodium current, which is abbreviated as ANEL.

Okay, unpack that for us.

Why does blocking a sodium current matter for angina?

We've been talking about calcium for an hour.

It's a domino effect.

In an ischemic, a starving heart muscle cell, this late sodium current tends to stay open too long during each heartbeat.

This causes the cell to get overloaded with sodium.

Okay, so the cell is full of sodium.

So what?

The cell hates that.

It has to get rid of that excess sodium, so it uses a pump on its surface, called the sodium calcium exchanger.

Normally, this pump pushes calcium out and brings sodium in, but when the cell is full of sodium, the pump runs in reverse.

Ah, so it starts pumping sodium out and bringing calcium in.

Exactly.

So the intracellular sodium overload leads directly to an intracellular calcium overload.

And that excess calcium keeps the muscle tense.

It can't relax fully during diastole.

This increases diastolic wall tension and squishes the capillaries, worsening ischemia.

So ranlozine stops the sodium from coming in, which prevents the calcium buildup, which allows the heart muscle to relax more completely between beats.

Precisely.

It improves diastolic function.

And like ivabridine, its unique benefit is that it doesn't significantly change the heart rate or the blood pressure.

It's a great add -on therapy when the traditional drugs aren't doing enough or are causing side effects.

Is there a catch?

Yes, there's a safety consideration.

It can block a potassium channel called ITE, which is involved in repolarization.

This can prolong the QT interval on the ECG, which in rare cases can increase the risk of a dangerous arrhythmia.

So you have to be careful with it.

Finally, the text mentions trimetazidine, the metabolic modulator.

This one isn't even FDA approved in the US, right?

Not approved in the US, no, but it's used widely in Europe and Asia.

This drug represents a completely different paradigm.

Everything else we've talked about changes the hemodynamics, the pressure, the flow, the rate.

Trimetazidine changes the heart's metabolism.

It changes the fuel source.

Exactly.

The heart acts like a flex fuel vehicle.

It can burn two main fuels for energy,

fatty acids or glucose.

Under normal conditions, a healthy heart prefers to burn fatty acids.

It gets most of its energy that way.

Which is fine, usually.

Usually.

But burning fat is oxygen expensive.

It requires more molecules of oxygen to produce a given amount of ATP, or energy currency, compared to burning glucose.

When the heart is already starving for oxygen, burning fat is inefficient.

It's like trying to burn wet wood in a struggling fire.

So trimetazidine forces the heart to switch diets.

Yes.

It inhibits an enzyme called long -chain 3 -ketoacyl coenzyme A -thiolus.

That's a key enzyme in fatty acid oxidation.

By blocking it, it shuts down the heart's ability to burn fat and forces it to switch over to burning glucose, which is much more oxygen efficient.

It's like forcing a gas -guzzling truck to run in a high -efficiency electric hybrid mode.

That's a perfect analogy.

You get more energy, more ATP, for the same limited amount of oxygen.

It's a metabolic hack.

It makes the heart muscle more efficient without changing the blood pressure or heart rate at all.

That brings us to our final section, clinical management.

How do doctors put all of this information together?

The text has a great case study in Box 11 .1 about a construction foreman.

Let's call him Gary.

Okay, Gary.

So the book tells us he's 57 years old, he smokes, his blood pressure is high, 150 over 95, and he complains of sub -sternal chest pressure when he's hauling lumber on the job site.

The pain goes away when he rests.

So based on what we've learned, that sounds like a textbook case of typical stable angina.

Absolutely.

Exertional, predictable, relieved by rest.

So the treatment plan in the text illustrates the typical stacking approach.

First, he needs a rescue plan for acute attacks.

Sublingual nitroglycerin.

Right.

That's for when an attack happens.

He carries that in his pocket, he feels the pain coming on, he stops working, sits down and puts a nitro tablet under his tongue.

The pain should go away in three to five minutes.

And if it doesn't?

That's a red flag.

The rule is usually take one, wait five minutes.

If still in pain, take a second, wait five more minutes.

If still in pain after a third, it's time to call 911 because this could be a heart attack.

But we don't want him having attacks at all.

We want to prevent them.

Correct.

So he needs prophylaxis.

For Gary, the text suggests amlodipine, a long acting

dihydropyridine CCB.

Why that one specifically?

Why not a beta blocker or a nitrate patch?

Well, remember, he also has high blood pressure.

Amlodipine is an excellent medication for lowering blood pressure and for treating angina by reducing afterload.

It kills two birds with one stone for him.

Plus aspirin.

Right.

Low dose aspirin for clot prevention to reduce his long -term risk of a heart attack.

And the text is very clear on this.

The most crucial parts of his management are lifestyle changes, smoking cessation and managing his blood pressure.

If Gary keeps smoking, the drugs are fighting a losing battle.

So there's a hierarchy here in treatment.

There is.

For someone with a very occasional mild angina, you might just use nitroglycerin PRN, meaning as needed.

If it happens frequently enough to affect their quality of life, you need

prophylaxis.

The guidelines often favor a beta blocker as the first line drug for typical stable angina because of their proven survival benefit after a heart attack.

But the choice really depends on the patient.

And this is where comorbidities come in.

This is where you have to tailor the drug to the specific patient.

What if our construction foreman, Gary, also had asthma?

Okay, great question.

Then you would have to be very careful with beta blockers.

Non -selective beta blockers like propranolol can block beta two receptors in the lungs, which causes

bronchoconstriction.

They can trigger a severe asthma attack.

So in an asthmatic with angina, a CCB like amlodipine would be a much safer and therefore preferred choice.

What if he had diabetes?

Again, CCBs are generally very safe.

Beta blockers can be tricky because they can mask the symptoms of hypoglycemia or low blood sugar.

If a diabetic patient takes too much insulin and their blood sugar drops, their body's first response is an adrenaline surge.

They get shaky, sweaty, and their heart starts to race.

That's the warning signal that tells them, I need sugar, fast.

Beta blockers blunt that entire response.

They hide the warning signs.

The patient might become severely hypoglycemic and pass out without ever feeling it coming.

And what if the patient has heart failure on top of their angina?

Now you're on a real tightrope.

Some beta blockers are actually very good for heart failure in the long run, but you have to start them at a very low dose and increase them very slowly.

But a drug like verapamil, the text warns to be very careful.

Because it so strongly depresses contractility, it can push a failing heart over the edge into crisis.

You don't want to use a strong brake on a car that can barely make it up the hill.

In that case, ranolazine or long acting nitrates might be safer add on therapies.

So bringing it all home, we've covered a huge amount of ground.

We have.

We started with the engine metaphor, the heart as an engine with clogged fuel line.

We established the core principle,

the supply and demand scale.

And we learned that the subendocardium is the most vulnerable zone, the last house on the street.

We treat angina by dilating the veins with nitrates to lower preload.

We have to remember the Monday disease and the deadly danger of mixing them with Viagra.

We dilate the arteries with CCBs to lower afterload.

And we remember the crucial difference between the vessel selective dipines and the heart slowing verapamil and diltiasm.

Or we slow the engine revs and give the heart more time to feed itself with beta blockers, which are great for stable angina, but an absolute no go for variant angina.

And finally, we looked at the new school of tools of Aberdeen for the funding current, ranolazine for the sodium overload, and trimetazidine for the metabolic fuel switch.

It really is a complete toolkit for managing the physics and now the metabolism of the heart.

Here's my final thought, something for you to chew on as we close out.

The emergence of these metabolic agents drugs like trimetazidine that don't touch blood pressure or heart rate would actually change the cellular machinery itself.

That suggests we are moving into a completely new era of treatment.

I agree.

We aren't just plumbers and mechanics hitting pipes with wrenches and slowing down engines anymore.

We are becoming cellular engineers, fine tuning the efficiency of the engine at the molecular level.

That's a profound shift, moving from a focus on hemodynamics to a focus on metabolomics.

It suggests that in the future, we might treat heart disease, not just by unloading the heart from the outside, but by fundamentally optimizing its fuel efficiency from the inside.

A whole new frontier.

Well, on that note, we're going to wrap up this deep dive into chapter 11.

We hope this helps you visualize what's happening in those coronary arteries and how these amazing drugs work.

Keep studying.

And remember, if you can understand the mechanism, the how and the why, then all the drug names and This has been a production of the Last Minute Lecture Team.

Catch you on the next deep dive.